- Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
- Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
- Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
- Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
- Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder
- Compass Pathways appoints Teri Loxam as Chief Financial Officer
- Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry
- Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
- COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
- COMPASS Pathways announces CFO transition
More ▼
Key statistics
On Wednesday, Compass Pathways PLC (CMPS:NSQ) closed at 8.10, 61.68% above the 52 week low of 5.01 set on Nov 13, 2023.
52-week range
Open | 8.30 |
---|---|
High | 8.38 |
Low | 7.89 |
Bid | 7.80 |
Offer | 8.15 |
Previous close | 8.25 |
Average volume | 411.31k |
---|---|
Shares outstanding | 68.34m |
Free float | 3.66m |
P/E (TTM) | -- |
Market cap | 563.83m USD |
EPS (TTM) | -2.39 USD |
Data delayed at least 15 minutes, as of Apr 24 2024 21:00 BST.
More ▼